Skip to main content

CARACTERIZACION DE RUTAS MOLECULARES QUE CONTROLAN LA MOTILIDAD CELULAR DURANTE EL TRAFICO LEUCOCITARIO Y LA INVASION TUMORAL

SAF2014-53059-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lateral mobility and nanoscale spatial arrangement of chemokine-activated α4β1 integrins on T cells

  • Sosa-Costa, Alberto
  • Isern de Val, Soledad
  • Sevilla-Movilla, Silvia
  • Borgman, Kyra J. E.
  • Manzo, Carlo
  • Teixidó, Joaquín
  • Garcia-Parajo, Maria F.
11p.-8 fig., Chemokine stimulation of integrin α4β1-dependent T lymphocyte adhesion is a key step during lymphocyte trafficking. A central question regarding α4β1 function is how its lateral mobility and organization influence its affinity and avidity following cell stimulation with chemokines and/or ligands. Using single particle tracking and super-resolution imaging approaches, we explored the lateral mobility and spatial arrangement of individual α4β1 integrins on T cells exposed to different activating stimuli. We show that CXCL12 stimulation leads to rapid and transient α4β1 activation, measured by induction of the activation epitope recognized by the HUTS-21 anti-β1 antibody and by increased talin-β1 association. CXCL12-dependent α4β1 activation directly correlated with restricted lateral diffusion and integrin immobilization. Moreover, co-stimulation by CXCL12 together with soluble VCAM-1 potentiated integrin immobilization with a five-fold increase in immobile integrins as compared to unstimulated conditions. Our data indicate that docking by talin of the chemokine-activated α4β1 to the actin cytoskeleton favors integrin immobilization, which likely facilitates ligand interaction and increased adhesiveness. Super-resolution imaging showed that the nanoscale organization of high-affinity α4β1 remains unaffected following chemokine and/or ligand addition. Instead, newly activated α4β1 integrins organize on the cell membrane as independent units without joining pre-established integrin sites to contribute to cluster formation. Altogether, our results provide a rationale to understand how the spatiotemporal organization of activated α4β1 integrins regulates T lymphocyte adhesion., This work was supported by Erasmus Mundus Doctorate Program Europhotonics Grant 159224-1-2009-1-FR-ERA MUNDUS-EMJD), Spanish Ministry of Economy and Competitiveness “Severo Ochoa” Programme for Centres of Excellence in R&D Grants SEV-2015–0522, FIS2014 –5617-R, SAF2014–53059-R, and RD12/0036/0061; Fundacio Privada CELLEX (Barcelona);HFSP Grant GA RGP0027/2012; and LaserLab Europe 4 Grant GA 654148., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Evaluation of the potential therapeutic benefits of macrophage reprogramming in Multiple Myeloma Running

  • Gutiérrez-González, A.
  • Martínez-Moreno, Mónica
  • Samaniego, Rafael
  • Arellano-Sánchez, Nohemí
  • Salinas-Muñoz, Laura
  • Relloso, Miguel
  • Valeri, Antonio
  • Martínez-López, Joaquín
  • Corbí, Angel L.
  • Hidalgo, Andrés
  • García-Pardo, Angeles
  • Teixidó, Joaquín
  • Sánchez-Mateos, Paloma
Tumor-associated macrophages (TAM) are important components of the multiple myeloma (MM) microenvironment that support malignant plasma cell survival and resistance to therapy. It has been proposed that macrophages (MØ) retain the capacity to change in response to stimuli that can restore their antitumor functions. Here, we investigated several approaches to reprogram MØ as a novel therapeutic strategy in MM. First, we found tumor-limiting and tumor-supporting capabilities for monocyte-derived M1-like MØ and M2-like MØ, respectively, when mixed with MM cells, both in vitro and in vivo. Multicolor confocal microscopy revealed that MM-associated MØ displayed a predominant M2-like phenotype in the bone marrow of MM patient samples, and a high expression of the pro-M2 cytokine macrophage migration inhibitory factor (MIF). To reprogram the protumoral M2-like MØ present in MM toward antitumoral M1-like MØ, we tested the pro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) plus blockade of the M2 cytokines macrophage colony-stimulating factor or MIF. The combination of GM-CSF plus the MIF inhibitor 4-iodo-6-phenyl-pyrimidine achieved the best reprogramming responses toward anM1profile, at both gene and protein expression levels, as well as remarkable tumoricidal effects. Furthermore, this combined treatment elicited MØ-dependent therapeutic responses in MM xenograftmousemodels, which were linked to upregulation ofM1and reciprocal downregulation of M2 MØmarkers. Our results reveal the therapeutic potential of reprogramming MØ in the context of MM., This work was supported by the following grants: grant P2010/BMD-2314 from the Comunidad de Madrid (P.S.-M., A.G.-P., J.T., and A.H.); PI13/01454 from Instituto de Salud Carlos III/FEDER (P.S.-M.); RIER RD12/0009 (P.S.-M.), SAF2014-53059-R (J.T.), SAF2012-31613 (A.G.-P.), RD12/0036/0061 (J.T., A.G.-P., and J.M.-L.). The Centro Nacional de Investigaciones Cardiovasculares is supported by the Spanish Ministry of Economy and Competitiveness and the Pro– Centro Nacional de Investigaciones Cardiovasculares Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma, miRNA contribution to BRAF inhibitor melanoma resistance

  • Díaz-Martínez, Marta
  • Benito-Jardón, Lucía
  • Alonso, Lola
  • Koetz-Ploch, Lisa
  • Hernando, Eva
  • Teixidó, Joaquín
42 p.-7 fig., Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic benefits but the common emergence of drug resistance remains a challenge. We generated A375 melanoma cells resistant to vemurafenib with the goal of investigating changes in miRNA expression patterns that might contribute to resistance. Increased expression of miR-204-5p and miR-211-5p occurring in vemurafenib-resistant cells was determined to impact vemurafenib response. Their expression was rapidly affected by vemurafenib treatment through RNA stabilization. Similar effects were elicited by MEK and ERK inhibitors but not AKT or Rac inhibitors. Ectopic expression of both miRNA in drug-naïve human melanoma cells was sufficient to confer vemurafenib resistance and more robust tumor growth in vivo Conversely, silencing their expression in resistant cells inhibited cell growth. Joint overexpression of miR-204-5p and miR-211-5p durably stimulated Ras and MAPK upregulation after vemurafenib exposure. Overall, our findings show how upregulation of miR-204-5p and miR-211-5p following vemurafenib treatment enables the emergence of resistance, with potential implications for mechanism-based strategies to improve vemurafenib responses.Significance: Identification of miRNAs that enable resistance to BRAF inhibitors in melanoma suggests a mechanism-based strategy to limit resistance and improve clinical outcomes., This work was supported by grants SAF2014-53059-R and RD12/0036/0061 to J. Teixidó, and NIH/NCI grants R01CA155234-03 and R01CA163891-03 to E. Hernando., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Resistance to MAPK inhibitors in melanoma involves activation of the IGF-1R-MEK5-Erk5 pathway, Running title: Resistance mechanisms to MAPK inhibitors in melanoma

  • Benito-Jardón, Lucía
  • Díaz-Martínez, Marta
  • Arellano-Sánchez, Nohemí
  • Vaquero-Morales, Paloma
  • Esparís-Ogando, Azucena
  • Teixidó, Joaquín
39 p.-7 fig., Combined treatment of metastatic melanoma with BRAF and MEK inhibitors has improved survival, but the emergence of resistance represents an important clinical challenge. Targeting ERK is a suitable strategy currently being investigated in melanoma and other cancers. To anticipate possible resistance to ERK inhibitors (ERKi), we used SCH772984 (SCH) as a model ERKi to characterize resistance mechanisms in two BRAF V600E melanoma cell lines. The ERKi-resistant cells were also resistant to vemurafenib (VMF), trametinib (TMT), and to combined treatment with either VMF and SCH or TMT and SCH. Resistance to SCH involved stimulation of the IGF-1R-MEK5-Erk5 signaling pathway, which counteracted inhibition of Erk1/2 activation and cell growth. Inhibition of IGF-1R with linsitinib blocked Erk5 activation in SCH-resistant cells and decreased their growth in 3D spheroid growth assays as well as in NOD scid gamma (NSG) mice. Cells doubly resistant to VMF and TMT or to VMF and SCH also exhibited downregulated Erk1/2 activation linked to stimulation of the IGF-1R-MEK5-Erk5 pathway, which accounted for resistance. In addition, we found that the decreased Erk1/2 activation in SCH-resistant cells involved reduced expression and function of TGF-alpha. These data reveal an escape signaling route that melanoma cells use to bypass Erk1/2 blockade during targeted melanoma treatment and offer several possible targets whose disruption may circumvent resistance., This work was supported by grants SAF2014-53059-R, SAF2017-85146-R and RD12/0036/0061 to J.T., and PI15/01180 to A.E-O., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib, Running head: Myeloma resistance to bortezomib and α4β1 expression and function

  • Sevilla-Movilla, Silvia
  • Arellano-Sánchez, Nohemí
  • Martínez-Moreno, Mónica
  • Gajate, Consuelo
  • Sánchez‐Vencells, Anna
  • Vitores Valcárcel, Luis
  • Agirre, Xavier
  • Valeri, Antonio
  • Martínez-López, Joaquín
  • Prósper, Felipe
  • Mollinedo, Faustino
  • Teixidó, Joaquín
36 p.-6 fig., The interaction of multiple myeloma (MM) cells with the bone marrow (BM) microenvironment promotes MM cell retention, survival and resistance to different anti‐MM agents, including proteasome inhibitors (PIs) such as bortezomib (BTZ). The α4β1 integrin is a main adhesion receptor mediating MM cell‐stroma interactions and MM cell survival, and its expression and function are downregulated by BTZ, leading to inhibition of cell adhesion‐mediated drug resistance (CAM‐DR) and MM cell apoptosis. Whether decreased α4β1 expression and activity is maintained or recovered upon development of resistance to BTZ represents an important question, as a potential rescue of α4β1 function could boost MM cell survival and disease progression. Using BTZ‐resistant MM cells, we found that they not only rescue their α4β1 expression, but its levels were higher than in parental cells. Increased α4β1 expression in resistant cells correlated with enhanced α4β1‐mediated cell lodging in the BM, and with disease progression. BTZ‐resistant MM cells displayed enhanced NF‐κB pathway activation relative to parental counterparts, which contributed to upregulated α4 expression and to α4β1‐dependent MM cell adhesion. These data emphasize the upregulation of α4β1 expression and function as a key event during resistance to BTZ in MM, which might indirectly contribute to stabilize this resistance, as stronger MM cell attachment to BM stroma will regain CAM‐DR and MM cell growth and survival. Finally, we found a strong correlation between high ITGB1 (integrin β1) expression in MM and poor progression‐free survival (PFS) and overall survival (OS) during treatment of MM patients with BTZ and IMIDs, and combination of high ITGB1 levels and presence of the high‐risk genetic factor amp1q causes low PFS and OS. These results unravel a novel prognostic value for ITGB1 in myeloma., This work was supported by grants SAF2014-53059-R and SAF2017-85146-R from the Ministerio de Ciencia, Innovación y Universidades (MCIU) to JT; SAF2017-89672-R from MCIU to FM; by the Research Institute Hospital 12 de Octubre (i+12) and grants from Instituto de Salud Carlos III (ISCIII) and CIBERONC to JML; by grants from ISCIII PI16/02024,PI17/00701 and PI19/01352, TRASCAN (EPICA and Immunocell), Fundació La Marató de TV3, the Accelerator award CRUK/AIRC/AECC joint funder-partnership, CIBERONC(CB16/12/00489) and co-financed with FEDER funds MINECO Explora (RTHALMY),Gobierno de Navarra, Departamento de Salud 40/2016 and Departamento de Industria (Proyecto Estrategico, Reto Genomica, DIANA) and Fundación Ramón Areces (PREMAMM) to FP and XA The study was also supported by the Multiple Myeloma Research Foundation Networks of excellence, the International Myeloma Foundation (Brian van Novis), and the Qatar National Research Fund award 7-916-3-237., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular players in hematologic tumor cell trafficking

  • Redondo-Muñoz, Javier
  • García-Pardo, Angeles
  • Teixidó, Joaquín
18 p.-3 fig., The trafficking of neoplastic cells represents a key process that contributes to progression of hematologic malignancies. Diapedesis of neoplastic cells across endothelium and perivascular cells is facilitated by adhesion molecules and chemokines, which act in concert to tightly regulate directional motility. Intravital microscopy provides spatio-temporal views of neoplastic cell trafficking, and is crucial for testing and developing therapies against hematologic cancers. Multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL) are hematologic malignancies characterized by continuous neoplastic cell trafficking during disease progression. A common feature of these neoplasias is the homing and infiltration of blood cancer cells into the bone marrow (BM), which favors growth and survival of the malignant cells. MM cells traffic between different BM niches and egress from BM at late disease stages. Besides the BM, CLL cells commonly home to lymph nodes (LNs) and spleen. Likewise, ALL cells also infiltrate extramedullary organs, such as the central nervous system, spleen, liver, and testicles. The α4β1 integrin and the chemokine receptor CXCR4 are key molecules for MM, ALL, and CLL cell trafficking into and out of the BM. In addition, the chemokine receptor CCR7 controls CLL cell homing to LNs, and CXCR4, CCR7, and CXCR3 contribute to ALL cell migration across endothelia and the blood brain barrier. Some of these receptors are used as diagnostic markers for relapse and survival in ALL patients, and their level of expression allows clinicians to choose the appropriate treatments. In CLL, elevated α4β1 expression is an established adverse prognostic marker, reinforcing its role in the disease expansion. Combining current chemotherapies with inhibitors of malignant cell trafficking could represent a useful therapy against these neoplasias. Moreover, immunotherapy using humanized antibodies, CAR-T cells, or immune check-point inhibitors together with agents targeting the migration of tumor cells could also restrict their survival. In this review, we provide a view of the molecular players that regulate the trafficking of neoplastic cells during development and progression of MM, CLL, and ALL, together with current therapies that target the malignant cells., Work from the author's laboratories was supported by grants SAF2014-53059-R and SAF2017-85146-R to JT; SAF2012-31613-R and SAF2015-69180-R to AG-P; RYC-2015-18497 and SAF2017-86327-R to JR-M from the Ministry of Economy and Competitivity. Also by grant P2010/BMD-2314 from the Comunidad de Madrid/European Union to JT and AG-P; and by a Gilead Sciences International Scholar grant in Hematology/Oncology to JR-M., Peer reviewed